DOI: 10.4244/EIJV12SYA5

Transcatheter aortic valve implantation: there is still much to know

Corrado Tamburino1*, MD; Jean Fajadet2, MD

Once upon a time, there was a new-born and extremely promising interventional technique just entering the scientific community of cardiologists and cardiac surgeons. This novel approach imagined the successful transcatheter implantation of a bioprosthetic aortic valve in patients with severe aortic stenosis. From its infancy, the transcatheter aortic valve implantation (TAVI) technique has grown, offering a halo of contrasting feelings. On one hand, there were a few optimistic and visionary physicians who were firmly convinced that this procedure was here to stay. On the other hand, there was an army of sceptics who did not – or would not – see a bright future for TAVI as they took into consideration the excellent outcomes of the traditional surgical valve replacement alongside a number of safety issues raised by the very first TAVI procedures. Today, almost 15 years from that first-in-human implantation, history is witness that TAVI plays a key role in the treatment of severe aortic stenosis; now considered as being the most effective treatment in inoperable patients and a reliable alternative to conventional surgical aortic valve replacement in high- and intermediate-risk patients. Along with increased operator experience, the technology has contributed in helping us make this definitive quantum leap. A number of new TAVI devices, so-called “second-generation devices”, have incorporated features addressing the limitations of the first-generation devices including paravalvular leak (i.e., lower profile, easier positioning, repositionability and retrievability).

Overall, the acute complication rates have been reduced, global health authorities are already extending indications for TAVI in larger populations and giving a green light to randomised trials in low-risk patients, and data on long-term durability seem promising. With all this, you might think that there is very little left to look at in this field. On the contrary, we believe that this is the very time when we need to reinforce our clinical and scientific commitment. In fact, there is still much to know about TAVI – such as the efficacy of TAVI in particular populations such as bicuspid aortic valves or low-risk patients – all of which is still poorly explored. In addition, new unexpected (or sometimes anticipated, but neglected) issues are arising from recent literature and need a prompt and appropriate reaction (i.e., early valve deterioration and thrombosis).

This section of the Supplement has been designed with this in mind; it is an attempt to address these issues and shed more light on the current knowledge of TAVI.

Conflict of interest statement

C. Tamburino receives speaker’s honoraria from Abbott and Medtronic. J. Fajadet has no conflicts of interest to declare.

Volume 12 Supplement Y
Sep 18, 2016
Volume 12 Supplement Y
View full issue


Key metrics

Suggested by Cory

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free

10.4244/EIJV7I12A228 Apr 20, 2012
The 3mensio Valves™ multimodality workstation
de Vaan J et al
free

EXPERT REVIEW

10.4244/EIJ-D-18-01048 Apr 5, 2019
The evolution of device technology in transcatheter aortic valve implantation
Bourantas C et al
free

EXPERT REVIEW

10.4244/EIJ-D-17-00567 Sep 24, 2017
Transcatheter aortic valve implantation in 2017: state of the art
Barbanti M et al
free

10.4244/EIJV8SQA4 Sep 30, 2012
Historical perspective: 10th year anniversary of TAVI
Cribier A
free

10.4244/EIJV9SSA16 Sep 15, 2013
Transcatheter aortic valve update 2013
Bourantas C et al
free

10.4244/EIJV9I7A142 Nov 29, 2013
Pre-defining optimal C-arm position for TAVI with CT-scan using free software
Imme S et al
free
Trending articles
152.9

Clinical research

10.4244/EIJ-D-20-01125 Oct 20, 2021
An upfront combined strategy for endovascular haemostasis in transfemoral transcatheter aortic valve implantation
Costa G et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
39.1

Clinical research

10.4244/EIJ-D-22-00558 Feb 6, 2023
Permanent pacemaker implantation and left bundle branch block with self-expanding valves – a SCOPE 2 subanalysis
Pellegrini C et al
free
38.95

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved